Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders. Its reported yearly financial results show: Cash position of $ 222.7 million by December 31, 2023, an 11.5% decrease as compared to that held by December 31, 2022.Yearly R&D expenses totaled $29.8 million, a 45% increase as compared to the $20.5 million spent in 2022.Yearly G&A expenses totaled $11.4 million, a 12.8% increase as compared to the $10.1 million spent in 2022.Yearly net loss of $35.6 million (or …
